이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!
Glenmark Pharmaceuticals 관리
관리 기준 확인 1/4
Glenmark Pharmaceuticals' CEO는 Glenn Saldanha, Jan2001 에 임명되었습니다 의 임기는 23.42 년입니다. 총 연간 보상은 ₹ 161.85M, 80.2% 로 구성됩니다. 80.2% 급여 및 19.8% 보너스(회사 주식 및 옵션 포함). 는 ₹ 1.22B 가치에 해당하는 회사 주식의 0.35% 직접 소유합니다. 1.22B. 경영진과 이사회의 평균 재임 기간은 각각 1.6 년과 12.5 년입니다.
주요 정보
Glenn Saldanha
최고 경영자
₹161.9m
총 보상
| CEO 급여 비율 | 80.2% |
| CEO 임기 | 23.6yrs |
| CEO 소유권 | 0.4% |
| 경영진 평균 재임 기간 | 1.8yrs |
| 이사회 평균 재임 기간 | 12.6yrs |
최근 관리 업데이트
Shareholders Will Probably Hold Off On Increasing Glenmark Pharmaceuticals Limited's (NSE:GLENMARK) CEO Compensation For The Time Being
Sep 23
Shareholders Will Probably Hold Off On Increasing Glenmark Pharmaceuticals Limited's (NSE:GLENMARK) CEO Compensation For The Time Being
Sep 21Recent updates
Calculating The Fair Value Of Glenmark Pharmaceuticals Limited (NSE:GLENMARK)
Aug 06Does Glenmark Pharmaceuticals (NSE:GLENMARK) Have A Healthy Balance Sheet?
Jun 16Is Glenmark Pharmaceuticals Limited (NSE:GLENMARK) Expensive For A Reason? A Look At Its Intrinsic Value
May 08Glenmark Pharmaceuticals (NSE:GLENMARK) Takes On Some Risk With Its Use Of Debt
Mar 09Is Glenmark Pharmaceuticals (NSE:GLENMARK) Using Too Much Debt?
Dec 07Shareholders Will Probably Hold Off On Increasing Glenmark Pharmaceuticals Limited's (NSE:GLENMARK) CEO Compensation For The Time Being
Sep 23Glenmark Pharmaceuticals (NSE:GLENMARK) Will Pay A Dividend Of ₹2.50
Sep 17Glenmark Pharmaceuticals (NSE:GLENMARK) Has Announced A Dividend Of ₹2.50
Aug 30A Look At The Intrinsic Value Of Glenmark Pharmaceuticals Limited (NSE:GLENMARK)
Aug 28We Think Glenmark Pharmaceuticals (NSE:GLENMARK) Is Taking Some Risk With Its Debt
Jul 03A Look At The Fair Value Of Glenmark Pharmaceuticals Limited (NSE:GLENMARK)
May 28Glenmark Pharmaceuticals (NSE:GLENMARK) Has A Somewhat Strained Balance Sheet
Mar 22Estimating The Fair Value Of Glenmark Pharmaceuticals Limited (NSE:GLENMARK)
Feb 14An Intrinsic Calculation For Glenmark Pharmaceuticals Limited (NSE:GLENMARK) Suggests It's 37% Undervalued
Oct 12Shareholders Will Probably Hold Off On Increasing Glenmark Pharmaceuticals Limited's (NSE:GLENMARK) CEO Compensation For The Time Being
Sep 21Glenmark Pharmaceuticals (NSE:GLENMARK) Has Announced A Dividend Of ₹2.50
Aug 29We Think Glenmark Pharmaceuticals (NSE:GLENMARK) Can Stay On Top Of Its Debt
Jun 20There May Be Reason For Hope In Glenmark Pharmaceuticals' (NSE:GLENMARK) Disappointing Earnings
Jun 04An Intrinsic Calculation For Glenmark Pharmaceuticals Limited (NSE:GLENMARK) Suggests It's 27% Undervalued
May 05If You Like EPS Growth Then Check Out Glenmark Pharmaceuticals (NSE:GLENMARK) Before It's Too Late
Mar 25A Look At The Intrinsic Value Of Glenmark Pharmaceuticals Limited (NSE:GLENMARK)
Jan 18We Think Glenmark Pharmaceuticals (NSE:GLENMARK) Can Stay On Top Of Its Debt
Dec 13CEO 보상 분석
| 날짜 | 총 보상 | 급여 | 회사 수익 |
|---|---|---|---|
| Mar 31 2024 | n/a | n/a | -₹19b |
| Dec 31 2023 | n/a | n/a | -₹8b |
| Sep 30 2023 | n/a | n/a | -₹1b |
| Jun 30 2023 | n/a | n/a | ₹3b |
| Mar 31 2023 | ₹162m | ₹130m | ₹3b |
| Dec 31 2022 | n/a | n/a | ₹9b |
| Sep 30 2022 | n/a | n/a | ₹8b |
| Jun 30 2022 | n/a | n/a | ₹8b |
| Mar 31 2022 | ₹158m | ₹130m | ₹9b |
| Dec 31 2021 | n/a | n/a | ₹10b |
| Sep 30 2021 | n/a | n/a | ₹10b |
| Jun 30 2021 | n/a | n/a | ₹10b |
| Mar 31 2021 | ₹139m | ₹110m | ₹10b |
| Dec 31 2020 | n/a | n/a | ₹10b |
| Sep 30 2020 | n/a | n/a | ₹9b |
| Jun 30 2020 | n/a | n/a | ₹9b |
| Mar 31 2020 | ₹122m | ₹91m | ₹8b |
| Dec 31 2019 | n/a | n/a | ₹7b |
| Sep 30 2019 | n/a | n/a | ₹6b |
| Jun 30 2019 | n/a | n/a | ₹8b |
| Mar 31 2019 | ₹157m | ₹131m | ₹9b |
| Dec 31 2018 | n/a | n/a | ₹9b |
| Sep 30 2018 | n/a | n/a | ₹9b |
| Jun 30 2018 | n/a | n/a | ₹7b |
| Mar 31 2018 | ₹162m | ₹134m | ₹8b |
보상 대 시장: Glenn 의 총 보상 ($USD 1.94M )은 Indian 시장( $USD 544.21K ).
보상과 수익: 회사가 수익성이 없는 동안 Glenn 의 보상이 증가했습니다.
CEO
Glenn Saldanha (54 yo)
23.6yrs
테뉴어
₹161,850,000
보상
Mr. Glenn Mario Saldanha has been the Managing Director and Chief Executive Officer of Glenmark Pharmaceuticals Limited since 2000. Mr. Saldanha serves as Chairman at Ichnos Sciences Inc. Mr. Saldanha serv...
리더십 팀
| 이름 | 위치 | 테뉴어 | 보상 | 소유권 |
|---|---|---|---|---|
| Chairman | 23.6yrs | ₹161.85m | 0.35% ₹ 1.4b | |
| Global CFO & Executive Director | 6.8yrs | ₹102.47m | 데이터 없음 | |
| Executive Director of Corporate Services & Executive Director | no data | ₹45.86m | 0.27% ₹ 1.1b | |
| Company Secretary & Compliance Officer | 7.5yrs | ₹5.71m | 데이터 없음 | |
| President and Chief Human Resources Officer | 2.6yrs | 데이터 없음 | 데이터 없음 | |
| President & Head of Global Pharmaceutical Development | 1.9yrs | 데이터 없음 | 데이터 없음 | |
| President & Chief Quality Officer | less than a year | 데이터 없음 | 데이터 없음 | |
| President & Global Head of Formulation Operations | less than a year | 데이터 없음 | 데이터 없음 | |
| President & Business Head of India Formulations | less than a year | 데이터 없음 | 데이터 없음 | |
| President and Business Head of Europe & Emerging Markets | 1.6yrs | 데이터 없음 | 데이터 없음 | |
| President & Business Head of North America | less than a year | 데이터 없음 | 데이터 없음 | |
| Investor Relations Officer | no data | 데이터 없음 | 데이터 없음 |
1.8yrs
평균 재임 기간
55yo
평균 연령
경험이 풍부한 관리: GLENMARK 의 관리팀은 경험 (평균 재직 기간 1.6 년)으로 간주되지 않으므로 새로운 팀을 추천합니다.
이사회 구성원
| 이름 | 위치 | 테뉴어 | 보상 | 소유권 |
|---|---|---|---|---|
| Chairman | 25.8yrs | ₹161.85m | 0.35% ₹ 1.4b | |
| Global CFO & Executive Director | 6.3yrs | ₹102.47m | 데이터 없음 | |
| Executive Director of Corporate Services & Executive Director | 24.8yrs | ₹45.86m | 0.27% ₹ 1.1b | |
| Non Executive Director | 19yrs | ₹400.00k | 0.39% ₹ 1.6b | |
| Non-Executive Independent Director | 22.3yrs | ₹1.70m | 0.039% ₹ 154.8m | |
| Independent Non-Executive Director | 1.5yrs | ₹100.00k | 데이터 없음 | |
| Independent Non-Executive Director | 4yrs | ₹900.00k | 데이터 없음 | |
| Independent Non-Executive Director | 5.3yrs | ₹1.30m | 데이터 없음 |
12.6yrs
평균 재임 기간
61yo
평균 연령
경험이 풍부한 이사회: GLENMARK 의 이사회는 노련하고 경험이 있습니다(평균 재직 기간 12.5 년).